Patent US5545569A successfully refreshed from Google Patents.
US5545569A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
Assignee: Poniard Pharmaceuticals Inc
•
Filing: 1995-05-25
•
Granted: 1996-08-13
•
Expires: 2015-05-25
Abstract
Abstract TGF-beta activators and TGF-beta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs, atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose are also amenable to chronic use for prophylactic purposes with respect to disease states involving proliferation and/or migration of vascular smooth muscle cells over time. Further provided is a method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis and monitoring a recipient that has received one or more administrations of a TGF-beta activator or production stimulator.
Inventors
- 👤 David J. Grainger
- 👤 James C. Metcalfe
- 👤 Peter L. Weissberg
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 22:12
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K31/13; A61K31/135; A61K31/138; A61K31/33; A61K31/395; A61K31/40; A61P; A61P43/00; A61P7/00; A61P7/02; A61P9/00; A61P9/08; A61P9/10; A61P9/12; A61P9/14; C; C07; C07K; C07K14/00; C07K14/435; C07K14/705; C07K14/71; C07K16/00; C07K16/18; C07K16/22; C07K2317/00; C07K2317/70; C07K2317/73; C07K2317/74; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/321; G01N2800/323
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
115 words
A method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis or for monitoring a recipient that has received one or more administrations of a therapeutic agent that increases the level of TGF-beta, which method comprises: (a) immobilizing a capture moiety that binds TGF-beta; (b) combining serum from the patient or the recipient with the immobilized capture moiety, forming a capture complex comprising the capture moiety and TGF-beta; (c) combining the capture complex with a signal moiety that binds TGF-beta and has a detectable label, forming a signal complex; and (d) determining the presence of a detectable label in the signal complex, thereby determining the presence of TGF-beta in the serum.
Claim 2
Independent Claim
115 words
A method for determining TGF-beta in vitro, thereby identifying a patient at risk for atherosclerosis or for monitoring a recipient that has received one or more administrations of a therapeutic agent that increases the level of TGF-beta, which method comprises: (a) immobilizing a capture moiety that binds TGF-beta; (b) combining serum from the patient or the recipient with the immobilized capture moiety, forming a capture complex comprising the capture moiety and TGF-beta; (c) combining the capture complex with a signal moiety that binds TGF-beta and has a detectable label, forming a signal complex; and (d) determining the presence of a detectable label in the signal complex, thereby determining the presence of TGF-beta in the serum.
Claim 3
Dependent Claim
21 words
The method of claim 1 wherein the capture moiety and signal moiety are capable of binding both latent and active TGF-beta.
Claim 4
Dependent Claim
23 words
The method of claim 2 where the capture moiety is a first anti-TGF-beta antibody and the signal moiety is a second anti-TGF-beta antibody.
Claim 5
Dependent Claim
17 words
The method of claim 1 wherein the capture moiety or the signal moiety recognizes active TGF-beta only.
Claim 6
Dependent Claim
23 words
The method of claim 4 wherein the capture moiety is TGF-beta type II receptor extracellular domain and the signal moiety is anti-TGF-beta antibody.
Claim 7
Dependent Claim
14 words
The method of claim 1 wherein the therapeutic agent is a TGF-beta production stimulator.
Claim 8
Dependent Claim
13 words
The method of claim 1 wherein the therapeutic agent is a TGF-beta activator.
Claim 9
Dependent Claim
16 words
The method of claim 4 wherein the capture moiety is TGF-beta type II receptor extracellular domain.
Claim 10
Independent Claim
100 words
A method for determining the level of active TGF-beta in vitro, comprising: (a) immobilizing a capture moiety that binds TGF-beta; (b) combining serum from an individual with the immobilized capture moiety, forming a capture complex comprising the capture moiety and TGF-beta: (c) combining the capture complex with a signal moiety that binds TGF-beta and has a detectable label, forming a signal complex, wherein either or both the capture and signal moiety bind active but not latent TGF-beta; and (d) determining the presence of a detectable label in the signal complex, thereby determining the presence of active TGF-beta in the serum.
Claim 11
Independent Claim
100 words
A method for determining the level of active TGF-beta in vitro, comprising: (a) immobilizing a capture moiety that binds TGF-beta; (b) combining serum from an individual with the immobilized capture moiety, forming a capture complex comprising the capture moiety and TGF-beta: (c) combining the capture complex with a signal moiety that binds TGF-beta and has a detectable label, forming a signal complex, wherein either or both the capture and signal moiety bind active but not latent TGF-beta; and (d) determining the presence of a detectable label in the signal complex, thereby determining the presence of active TGF-beta in the serum.
Claim 12
Dependent Claim
13 words
The method of claim 9 wherein the signal moiety is an anti-TGF-beta antibody.
Claim 13
Dependent Claim
13 words
The method of claim 9 wherein the capture moiety is an anti-TGF-beta antibody.
Claim 14
Dependent Claim
22 words
The method of claim 9 wherein the moiety that binds active but not latent TGF-beta is TGF-beta type II receptor extracellular domain.
References Cited (Backward Citations)
USRE32944E
Cited
US4070484A
Cited
US3940422A
Cited
US4235988A
Cited
US5324736A
Cited
US5098903A
Cited
US4442119A
Cited
US5047431A
Cited
US4879315A
Cited
US5015666A
Cited
US4512762A
Cited
US5226430A
Cited
US5284763A
Cited
US4826672A
Cited
US5316766A
Cited
US4859585A
Cited
US4839155A
Cited
EP0260066A1
Cited
US5120535A
Cited
US4835002A
Cited
US5221620A
Cited
US4929602A
Cited
US4997652A
Cited
US5213580A
Cited
WO1990001969A1
Cited
US5208019A
Cited
EP0365863A2
Cited
US5340925A
Cited
US5268358A
Cited
US5304541A
Cited
US5032679A
Cited
EP0374044A2
Cited
US5380716A
Cited
EP0451202A1
Cited
US5364632A
Cited
US5026537A
Cited
US5248764A
Cited
US5043335A
Cited
US4990538A
Cited
US5049132A
Cited
WO1991015222A2
Cited
WO1991015219A1
Cited
US5166143A
Cited
US5140012A
Cited
US5189046A
Cited
US5189212A
Cited
US5192525A
Cited
US5219548A
Cited
US5238714A
Cited
US5180366A
Cited
US5053033A
Cited
US5362424A
Cited
WO1992008480A1
Cited
US5308622A
Cited
US5280016A
Cited
US5254594A
Cited
US5116864A
Cited
WO1992018546A1
Cited
WO1992019273A1
Cited
WO1992021363A1
Cited
US5213576A
Cited
US5296492A
Cited
US5229495A
Cited
US5216126A
Cited
US5185260A
Cited
WO1993007748A2
Cited
WO1993009228A1
Cited
EP0542679A1
Cited
WO1993009790A1
Cited
US5304325A
Cited
US5270047A
Cited
WO1993010808A1
Cited
US5238950A
Cited
US5284869A
Cited
US5326757A
Cited
US5354562A
Cited
US5346993A
Cited
US5280109A
Cited
US5444164A
Cited
WO1993019746A1
Cited
US5288711A
Cited
US5283257A
Cited
US5393763A
Cited
EP0584952A1
Cited
WO1994004164A1
Cited
US5385935A
Cited
EP0588518A1
Cited
WO1994007529A1
Cited
WO1994008604A1
Cited
WO1994008605A1
Cited
WO1994009764A1
Cited
US5354774A
Cited
US5308862A
Cited
US5354801A
Cited
US5441947A
Cited
US5391557A
Cited
US5393772A
Cited
US5389670A
Cited
US5384332A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-08-13 | 2000-02-12 | 2000-08-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-08-13 | 2004-02-12 | 2004-08-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-08-13 | 2008-02-12 | 2008-08-13 | $7700.00 | Window Closed / Lapsed |